Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track HALO with free AI briefings, catalyst countdowns, and dilution alerts.

HALO · HALOZYME THERAPEUTICS, INC.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.1B Cash on Hand
CF+ Cash Runway
Follow HALO by email Get an email when HALO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about HALO, unsubscribe in one click. Privacy

📣 What HALO Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Recombinant Human Hyaluronidase (rHuPH20) Dehydration Phase 4 · NCT01120431 Withdrawn
large protein molecule Rheumatoid Arthritis Phase 4 · NCT00369187 Completed
Nab-paclitaxel Pancreatic Ductal Carcinoma Phase 3 · NCT02715804 Terminated
Pegvorhyaluronidase Alfa (PEGPH20) Metastatic Pancreatic Adenocarcinoma Phase 1/2 · NCT01959139 Completed
Linagliptin Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
Mitomycin Bladder Cancer Phase 1/2 · NCT00318643 Completed
Fluorouracil Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
PEGylated recombinant human hyaluronidase… Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
Tiragolumab Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
Irinotecan Metastatic Pancreatic Adenocarcinoma Phase 1/2 · NCT01959139 Completed
Human C1-Esterase Inhibitor Hereditary Angioedema Phase 2 · NCT01426763 Completed
Enoxaparin Metastatic Pancreatic Cancer Phase 2 · NCT01839487 Completed
Motixafortide (BL-8040) Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or… Phase 1/2 · NCT03281369 Terminated
Ceftriaxone Healthy Phase 1 · NCT00493220 Completed
Cytokine-Inducible SH2-Containing Protein Cholangiocarcinoma Non-resectable Phase 1 · NCT03267940 Terminated
Cohort 2: bococizumab 300 mg Healthy Phase 1 · NCT02667223 Terminated

Also used in these trials (approved or third-party drugs, not HALO's own candidates): Hyaluronidase, Insulin Aspart, Insulin Glulisine, Insulin Lispro, Relatlimab, Gemcitabine Hydrochloride, Leucovorin, Oxaliplatin, Paclitaxel, Pembrolizumab, Ramucirumab, Insulin Human.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

HALO holds $1.1B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HALO files for a raise →

👥 Who Owns HALO

Insiders 0.9% Institutions (1009 holders) 99.1% Public and other holders 0%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 6,173,547 5.41% 2026-03-31
Helen Torley
PRESIDENT AND CEO, Director · +256,642 options
Insider 767,780 0.67% 2026-11-12
Matthew L. Posard
Director · +6,040 options
Insider 53,609 0.05% 2026-10-01
Mark Howard Snyder
SVP, CHIEF LEGAL OFFICER · +10,068 options
Insider 49,929 0.04% 2026-06-12
Bernadette Connaughton
Director · +6,040 options
Insider 40,418 0.04% 2026-08-10
Nicole LaBrosse
SVP, CHIEF FINANCIAL OFFICER · +52,352 options
Insider 38,494 0.03% 2026-02-20
Jeffrey William Henderson
Director · +6,040 options
Insider 36,572 0.03% 2026-05-05
Barbara Gayle Duncan
Director · +6,040 options
Insider 23,715 0.02% 2026-05-05
Mahesh Krishnan
Director · +7,540 options
Insider 14,462 0.01% 2026-06-29
Cortney Caudill
SVP, CHIEF OPERATING OFFICER · +75,676 options
Insider 7,055 0.01% 2026-03-09
James Paul Lang
Director · +6,040 options
Insider 4,685 0.00% 2026-05-05
David A Ramsay
EVP, PRESIDENT, DRUG DELIVERY · +56,055 options
Insider 4,592 0.00% 2026-06-30

Share count 114,010,000 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full HALO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HALO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.